 LONDON and NEW YORK, March 02, 2020 GLOBE NEWSWIRE -- MeiraGTx Holdings plc MGTX, a vertically integrated, clinical stage gene therapy company, today announced that the European Medicines Agency EMA has granted Priority Medicines PRIME and Advanced Therapy Medicinal Product ATMP designations to AAV-RPGR, MeiraGTxs investigational gene therapy for the treatment of x-linked retinitis pigmentosa XLRP caused by mutations in the RPGR gene. MeiraGTx and Janssen Pharmaceuticals, Inc. Janssen, part of the Janssen Pharmaceutical Companies of Johnson Johnson, are jointly developing AAV-RPGR as part of a broader collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases. 